Literature DB >> 30291135

Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4.

Sergio A Quezada1, Karl S Peggs1.   

Abstract

Despite a number of preclinical studies demonstrating that the activity of anti-CTLA-4 antibodies in murine models of cancer relies on effector T-cell activation and regulatory T cell depletion, the activity of the clinical antibodies remains controversial. To decipher such mechanisms is critical to the development of novel and more potent immunotherapies.See related article by Sharma et al., p. 1233. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30291135     DOI： 10.1158/1078-0432.CCR-18-2509

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.

Authors:  Annabelle Emery; Sally Moore; James E Turner; John P Campbell
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244

2.  Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4+ effector T cell infiltration into murine pancreatic tumors.

Authors:  Neeha Zaidi; Sergio A Quezada; Janelle M Y Kuroiwa; Li Zhang; Elizabeth M Jaffee; Ralph M Steinman; Bei Wang
Journal:  Ann N Y Acad Sci       Date:  2019-04-04       Impact factor: 6.499

3.  The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.

Authors:  Anne Månsson Kvarnhammar; Niina Veitonmäki; Karin Hägerbrand; Anna Dahlman; Karin Enell Smith; Sara Fritzell; Laura von Schantz; Mia Thagesson; Doreen Werchau; Kristine Smedenfors; Maria Johansson; Anna Rosén; Ida Åberg; Magnus Winnerstam; Eva Nyblom; Karin Barchan; Christina Furebring; Per Norlén; Peter Ellmark
Journal:  J Immunother Cancer       Date:  2019-04-11       Impact factor: 13.751

Review 4.  NK Cell-Fc Receptors Advance Tumor Immunotherapy.

Authors:  Emilio Sanseviero
Journal:  J Clin Med       Date:  2019-10-12       Impact factor: 4.241

Review 5.  B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.

Authors:  Zena N Willsmore; Robert J Harris; Silvia Crescioli; Khuluud Hussein; Helen Kakkassery; Deepika Thapa; Anthony Cheung; Jitesh Chauhan; Heather J Bax; Alicia Chenoweth; Roman Laddach; Gabriel Osborn; Alexa McCraw; Ricarda M Hoffmann; Mano Nakamura; Jenny L Geh; Alastair MacKenzie-Ross; Ciaran Healy; Sophia Tsoka; James F Spicer; Sophie Papa; Linda Barber; Katie E Lacy; Sophia N Karagiannis
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

Review 6.  Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments.

Authors:  Adrien Procureur; Audrey Simonaggio; Jean-Emmanuel Bibault; Stéphane Oudard; Yann-Alexandre Vano
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

Review 7.  Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.

Authors:  Allan Relecom; Maysaloun Merhi; Varghese Inchakalody; Shahab Uddin; Darawan Rinchai; Davide Bedognetti; Said Dermime
Journal:  J Exp Clin Cancer Res       Date:  2021-02-18

Review 8.  Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?

Authors:  Michael Kuske; Maximilian Haist; Thomas Jung; Stephan Grabbe; Matthias Bros
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

9.  Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.

Authors:  Alexey Revenko; Larissa S Carnevalli; Charles Sinclair; Ben Johnson; Alison Peter; Molly Taylor; Lisa Hettrick; Melissa Chapman; Stephanie Klein; Anisha Solanki; Danielle Gattis; Andrew Watt; Adina M Hughes; Lukasz Magiera; Gozde Kar; Lucy Ireland; Deanna A Mele; Vasu Sah; Maneesh Singh; Josephine Walton; Maelle Mairesse; Matthew King; Mark Edbrooke; Paul Lyne; Simon T Barry; Stephen Fawell; Frederick W Goldberg; A Robert MacLeod
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 13.751

10.  An anti-CTLA-4 heavy chain-only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile.

Authors:  Xin Gan; Qianqian Shan; He Li; Rick Janssens; Yuqiang Shen; Yun He; Fei Chen; Rien van Haperen; Dubravka Drabek; Jin Li; Yang Zhang; Jiuqiao Zhao; Beibei Qin; Ming-Jin Jheng; Victor Chen; Jingsong Wang; Yiping Rong; Frank Grosveld
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-04       Impact factor: 12.779
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.